She became interested in science, first earning doctorate studies in physiology at the Université de Paris VI.
[4] In 2019 Jallal was appointed chief executive of Immunocore, who focus on T-cell receptors for cellular therapies.
[5][6] Other cellular therapeutic companies were engineering T-cell receptors on T cells ex vivo, Immunocore identified a strategy to use TCRs for soluble biologics.
[5] Immunocore raised $320m of initial series A support, and Jallal was made responsible securing further funding.
[5] Immunocore have developed anti-cancer immune mobilising monoclonal TCRs (ImmTACs), which are bispecific (have two bioactive ends).